Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $41.67, moving 2.02% from the previous trading session.
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk to Rebrand as Novo
The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
Novo Nordisk (NVO) closed the most recent trading day at $44.01, moving 1.23% from the previous trading session.
Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety
Novo Nordisk remains a Strong Buy after a robust Q2, with another guidance boost and strong free cash flow growth. NVO's valuation reflects high risk, yet intrinsic value estimates suggest a significant discount to current market price. GLP-1 market leadership persists, but competitive and regulatory pressures, plus post-LOE strategy execution, are critical forward risks.
Novo Nordisk says Wegovy approved in China for liver disease MASH
Denmark's Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Novo scraps two more heart drug trials, further dimming growth beyond obesity
Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
The Danish drugmaker said the clinical trial met its primary goal after 68 weeks of treatment.
Novo Nordisk launches Wegovy weight-loss pill in Germany
Novo Nordisk has launched its Wegovy pill in Germany, a spokesperson for the Danish drugmaker said on Tuesday, with investors keenly focused on the oral weight-loss treatment in light of intensifying competition with U.S. rival Eli Lilly.
Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell
Novo Nordisk shares fell on Thursday after Deutsche Bank downgraded the Danish drugmaker to Sell from Hold and lowered its price target, citing concerns over the company's growth prospects. The company's US shares declined about 2% in trading, with Deutsche Bank cutting its target to 265 Danish kroner from 290 kroner.
Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns
The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.
